Filtered By:
Drug: Tacrolimus

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 111 results found since Jan 2013.

Addition of Melphalan to Fludarabine/Busulfan (FLU/BU4/MEL) Provides Survival Benefit for Patients with Myeloid Malignancy Following Allogeneic Bone Marrow Transplantation/Peripheral Blood Stem Cell Transplantation
In conclusion, FLU/BU4/MEL had curative potential even for patients with advanced myeloid malignancies, accompanied by the rapid complete chimerism achievement after allo-BMT/PBSCT. The NRM should be minimized to further improve the outcomes.DisclosuresYokota: Bristol-Myers Squibb: Research Funding; Pfizer Inc.: Research Funding; MSD K.K.: Research Funding; CHUGAI PHARMACEUTICAL CO., LTD.: Research Funding; Celgene: Research Funding. Shibayama: Bristol-Meyer Squibb K.K: Honoraria, Research Funding; Novartis Pharma K.K.: Honoraria, Research Funding; Fujimoto Pharmaceutical: Honoraria, Research Funding; Ono Pharmaceutical Co...
Source: Blood - November 21, 2018 Category: Hematology Authors: Ueda, T., Maeda, T., Fukushima, K., Fujita, J., Kusakabe, S., Yokota, T., Shibayama, H., Tomiyama, Y., Kanakura, Y. Tags: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I Source Type: research

Recipient Adipose-Derived Stem Cells Enhance Recipient Cell Engraftment and Prolong Allotransplant Survival in a Miniature Swine Hind-Limb Model.
Abstract Donor mesenchymal stem cells (MSCs) could prolong vascularized composite allotransplantation (VCA) survival in our previous studies. However, recipient adipose tissue is easier to harvest than donor tissue for preconditioning modulation. Hence, this study investigated the efficacy of recipient autologous adipose-derived stem cells (rADSCs) for VCA survival. The heterotopic hind-limb transplantation from female donor to male recipient was performed in outbred miniature swine. Group I ( n = 6) was untreated controls. Group II ( n = 4) obtained rADSCs infusions (given on weeks 0, +1, +2, and +3). Group III (...
Source: Cell Transplantation - August 1, 2017 Category: Cytology Authors: Kuo YR, Chen CC, Chen YC, Chien CM Tags: Cell Transplant Source Type: research

Tacrolimus before CTLA4Ig and rapamycin promotes vascularized composite allograft survival in MGH miniature swine
CONCLUSION: A short course of CNI, followed by combined Co-SB and mTORi significantly delays acute rejection of VRAM allografts in SLA-mismatched miniature swine.PMID:35987329 | DOI:10.1016/j.trim.2022.101696
Source: Transplant Immunology - August 20, 2022 Category: Transplant Surgery Authors: Tarek Y Elgendy Matthias Waldner Wensheng Zhang Deokyeol Y Kim Marta I Minervini Chiaki Komatsu Yalcin Kulahci Kia M Washington Vijay S Gorantla Mohamed B Ezzelarab Mario G Solari Angus W Thomson Source Type: research

Induction of Cardiac Allograft Tolerance Across a Full MHC Barrier in Miniature Swine by Donor Kidney Cotransplantation
Abstract We have previously shown that tolerance of kidney allografts across a full major histocompatibility complex (MHC) barrier can be induced in miniature swine by a 12‐day course of high‐dose tacrolimus. However, that treatment did not prolong survival of heart allografts across the same barrier. We have now tested the effect of cotransplanting an allogeneic heart and kidney from the same MHC‐mismatched donor using the same treatment regimen. Heart allografts (n = 3) or heart plus kidney allografts (n = 5) were transplanted into MHC‐mismatched recipients treated with high‐dose tacrolimus for 12 days....
Source: American Journal of Transplantation - August 1, 2013 Category: Transplant Surgery Authors: M. L. Madariaga, S. G. Michel, M. Tasaki, V. Villani, G. M. La Muraglia, S. Sihag, J. Gottschall, E. A. Farkash, A. Shimizu, J. S. Allan, D. H. Sachs, K. Yamada, J. C. Madsen Tags: Original Article Source Type: research

Kidney‐Induced Cardiac Allograft Tolerance in Miniature Swine is Dependent on MHC‐Matching of Donor Cardiac and Renal Parenchyma
Kidney allografts possess the ability to enable a short course of immunosuppression to induce tolerance of themselves and of cardiac allografts across a full‐MHC barrier in miniature swine. However, the renal element(s) responsible for kidney‐induced cardiac allograft tolerance (KICAT) are unknown. Here we investigated whether MHC disparities between parenchyma versus hematopoietic‐derived “passenger” cells of the heart and kidney allografts affected KICAT. Heart and kidney allografts were co‐transplanted into MHC‐mismatched recipients treated with high‐dose tacrolimus for 12 days. Group 1 animals (n = ...
Source: American Journal of Transplantation - March 30, 2015 Category: Transplant Surgery Authors: M. L. Madariaga, S. G. Michel, G. M. La Muraglia, M. Sekijima, V. Villani, D. A. Leonard, H. J. Powell, J. M. Kurtz, E. A. Farkash, R. B. Colvin, J. S. Allan, C. L. Cetrulo, Jr, C. A. Huang, D. H. Sachs, K. Yamada, J. C. Madsen Tags: Original Article Source Type: research

Effects of Lung Cotransplantation on Cardiac Allograft Tolerance Across a Full Major Histocompatibility Complex Barrier in Miniature Swine
A 12‐day course of high‐dose tacrolimus induces tolerance of major histocompatibility complex–mismatched lung allografts in miniature swine but does not induce tolerance of heart allografts unless a kidney is cotransplanted. To determine whether lungs share with kidneys the ability to induce cardiac allograft tolerance, we investigated heart–lung cotransplantation using the same induction protocol. Hearts (n = 3), heart–kidneys (n = 3), lungs (n = 6), and hearts–lungs (n = 3) were transplanted into fully major histocompatibility complex–mismatched recipients treated with high‐dose tacrolimus...
Source: American Journal of Transplantation - October 1, 2015 Category: Transplant Surgery Authors: M. L. L. Madariaga, P. J. Spencer, S. G. Michel, G. M. La Muraglia, M. J. O’Neil, E. C. Mannon, C. Leblang, I. A. Rosales, R. B. Colvin, D. H. Sachs, J. S. Allan, J. C. Madsen Tags: Brief Communication Source Type: research

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis
Conclusion: The current study proved that disease status at allo-HCT were mainly in non-remission. In such a situation, RIC using Flu/Mel/TBI was well tolerated with relatively low NRM, and was sufficient to allow engraftment for elderly or frail patients with hematopoietic malignancies.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Mino, T., Katayama, Y., Terasaki, T., Kochi, Y., Jinnouchi, F., Okatani, T., Imanaka, R., Kyo, K., Itagaki, M., Katsutani, S., Muta, T., Iwato, K., Asaoku, H. Tags: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I Source Type: research

Reduced Dose of Post-Transplant Cyclophosphamide for HLA Haploidentical Peripheral Blood Stem Cell Transplantation
Conclusion]Reduced dose of PT-CY HLA haploidentical peripheral blood stem cell transplantation resulted in acceptable rate and severity of acute GVHD. However, relapse and infection remain major problems after PT-CY haplo-SCT for hematologic malignancies.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Morishige, S., Yamasaki, Y., Oya, S., Nakamura, T., Ymaguchi, M., Aoyama, K., Seki, R., Mouri, F., Osaki, K., Nagafuji, K. Tags: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities Source Type: research

Haplo-Identical Stem Cell Transpant Is a Feasible and Safe Treatment Option for Patients with Severe Thalassemia
Conclusion: Haploidentical HSCT for high risk thalassemia patients is with our novel approach safe. The EFS rates among MRD, MUD and Haplo-HSCT recipients receiving this regimen, varied only in reference to the choice of matched vs mismatched donor is at least 95%, and we conclude that virtually every patient will now have the option of an allo-SCT regardless of donor compatibility. Therefore, we suggest that all thalassemia patients, even those with high risk class 3 features, should be offered allo-HSCT. However, this treatment program is not thalassemia-specific, but it is proof of principle for how to successfully tran...
Source: Blood - November 21, 2018 Category: Hematology Authors: Hongeng, S., Anurathapan, U., Pakakasama, S., Songdej, D., Sirachainan, N., Chuansumrit, A., Andersson, B. S. Tags: 732. Clinical Allogeneic Transplantation: Results: Poster II Source Type: research

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma
We present a prospective Phase II study using Flu/Mel/Vel (FMV) as a conditioning regimen for alloSCT. The primary endpoint is overall survival (OS), and secondary endpoints include progression free survival (PFS), incidence of graft-versus-host disease (GVHD) and transplant related mortality (TRM). For related donors, the conditioning regimen was Flu 30 mg/m2 days -5, -4, -3, -2, Vel 1.6 mg/m2 days -4, -1, Mel 140 mg/m2 day -2. For unrelated donors, rabbit ATG 4 mg/kg was given in divided doses days -3, -2, -1. GVHD prophylaxis consisted of methotrexate and tacrolimus. We compared pts receiving FMV to historical controls ...
Source: Blood - November 21, 2018 Category: Hematology Authors: McKiernan, P., Siegel, D. S., Vesole, D. H., Andrews, T., Biran, N., Rowley, S. D., Skarbnik, A. P., Pecora, A. L., Callahan, J., Ortega, A., Vendivil, M., Kaur, S., McKenna, M., Donato, M. L. Tags: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity and Novel Approaches with Targeted therapy Source Type: research

Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia with Pre-Transplant Conditioning Using Fludarabine, Reduced-Dose Cyclophosphamide, and Low-Dose Thymoglobulin:A Ksgct Prospective Study
Conclusion] HSCT for AA using Flu, reduced-dose CY, and low-dose thymoglobulin as a conditioning regimen was safe and effective. Relatively high incidences of MC and chronic GVHD need further improvement. (This study is registered with www.umin.ac.jp as UMIN000006071.)DisclosuresKako: Takeda Pharmaceutical Company Limited.: Honoraria; Takeda Pharmaceutical Company Limited.: Honoraria; Celgene K.K.: Honoraria; Bristol-Myers Squibb: Honoraria; Sumitomo Dainippon Pharma Co., Ltd.: Honoraria; Chugai Pharmaceutical Co., Ltd.: Honoraria; Otsuka Pharmaceutical Co., Ltd.: Honoraria; Ono Pharmaceutical Co., Ltd.: Honoraria; Janssen...
Source: Blood - November 21, 2018 Category: Hematology Authors: Kako, S., Kanda, Y., Onizuka, M., Aotsuka, N., Usuki, K., Tachibana, T., Kobayashi, T., Kato, J., Yano, S., Shimizu, H., Shono, K., Tanaka, M., Tsukamoto, S., Mori, T., Yamazaki, E., Okamoto, S. Tags: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I Source Type: research

Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation
Conclusions: The incidence of VOD in this large modern cohort of 1492 RIC HSCT patients was 1.6%, and was associated with the use of Sir with Tac. Onset of VOD in RIC patients was delayed (median D+26 vs. D+14) and 2 yr-OS is superior compared to MAC patients. Only 19% of the RIC VOD cases met the bilirubin threshold for Baltimore and Seattle criteria at diagnosis, suggesting that the rise in bilirubin is a later event in these RIC VOD cases, whereas increasing platelet transfusion requirements, sudden rise in Tac and Sir levels, elevated serum creatinine and acute renal injury appear to be early clinical predictors.Disclo...
Source: Blood - November 21, 2018 Category: Hematology Authors: Lewis, C., Kim, H. T., Cutler, C. S., Koreth, J., Nikiforow, S., Gooptu, M., Romee, R., Glotzbecker, B., Nageshwar, P., Alyea, E. P., Antin, J. H., Richardson, P., Soiffer, R. J., Ho, V. T. Tags: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II Source Type: research

Cord Blood Transplants Supported By Unrelated Donor CD34 Progenitor Cells
Conclusion: 20% of adults without matched related or unrelated donors, also lack suitable first or second degree haplo-identical donors. UCB transplant with partially matched unrelated donor accessory cells provides an alternative for transplantation. Engraftment is rapid, rates of acute GVHD are acceptable and incidence of chronic GVHD is very low. Prolonged survival is encouraging in this patient cohort with adverse characteristics and who would not be candidate for haplo-identical HSCT.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Gomez-Arteaga, A., Guarneri, D., Gergis, U., Hsu, J., Mayer, S. A., Phillips, A. A., Shore, T. B., Van Besien, K. Tags: 732. Clinical Allogeneic Transplantation: Results: Poster III Source Type: research

Hematopoietic Stem Cell Transplantation in Children with Refractory Langerhans Cell Histiocytosis
In conclusions, of 30 HSCT-recipients for refractory LCH, 17/30 (57%) are alive while post-transplant death occurred in 13/30 (43%). Our study showed that in regard to the correlation of disease status at HSCT and outcome, 6 patients with NAD/ AD-r had better outcome than 19 with AD-s/ AD-p (5-year OS 100% vs 52.1%, p=0.035). Novel bridging measures, such as targeted inhibition of the MAPK pathway, are required to stabilize the disease activity before HSCT.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Kudo, K., Maeda, M., Suzuki, N., Kanegane, H., Ohga, S., Ishii, E., Shioda, Y., Imamura, T., Imashuku, S., Tsunematsu, Y., Endo, M., Shimada, A., Koga, Y., Hashii, Y., Inagaki, J., Inoue, M., Tabuchi, K., Morimoto, A. Tags: 732. Clinical Allogeneic Transplantation: Results: Poster III Source Type: research

Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using < sup > 90 < /sup > Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma
CONCLUSION: Addition of Zevalin to Flu/Mel is safe and effective in high-risk NHL and met the prespecific endpoint. Results were suboptimal in patients with DLBCL.PMID:37301631 | DOI:10.1016/j.clml.2023.05.011
Source: Clinical Lymphoma and Myeloma - June 10, 2023 Category: Cancer & Oncology Authors: Matthew Mei Joycelynne Palmer Nicole Ni-Chun Tsai Jennifer Simpson James O'Hearn Anthony Stein Stephen Forman Ricardo Spielberger Ji-Lian Cai Myo Htut Ryotaro Nakamura Monzr M Al Malki Alex Herrera Jeffrey Wong Auayporn Nademanee Source Type: research